Radiopharmaceuticals

Radiopharmaceuticals are a specialized class of medicinal formulations that contain radioactive isotopes (radionuclides) used either for diagnostic imaging or therapeutic purposes. They combine the targeting specificity of pharmaceutical agents with the radioactive properties of radionuclides. Their dual functionality allows physicians to detect physiological abnormalities at a molecular level and to selectively irradiate diseased tissues, particularly in oncology, endocrinology, and cardiology.

As of 2025, the role of radiopharmaceuticals continues to expand with the growth of molecular imaging, theranostics, and personalized medicine. Innovations such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and targeted radionuclide therapy (TRT) are revolutionizing clinical diagnostics and cancer therapeutics.

---

1. Definition

Radiopharmaceuticals are medicinal products containing radioactive isotopes intended for administration to humans or animals to:

• Diagnose disease (e.g., PET or SPECT scans)

• Treat disease (e.g., targeted radiotherapy for cancer)

• Perform research and assess organ function

They are also known as:

• Radiotracers (in diagnostic imaging)

• Radiotherapeutics (in nuclear medicine therapy)

---

2. Classification of Radiopharmaceuticals

Radiopharmaceuticals are broadly categorized based on their clinical application and type of radiation emitted:

A. By Clinical Use

Category	Description	Examples
Diagnostic agents	Used for imaging or functional studies	Fluorodeoxyglucose (FDG), Tc-99m agents
Therapeutic agents	Used to treat diseases by emitting cytotoxic radiation	Lutetium-177, Iodine-131
Theranostic agents	Used for both diagnosis and therapy	Ga-68/Lu-177 DOTATATE

B. By Type of Radiation Emitted

Radiation Type	Characteristics	Application
Gamma (γ)	High energy, used in imaging	SPECT (e.g., Tc-99m, I-123)
Beta (β⁻)	Medium energy, causes tissue damage	Therapy (e.g., I-131, Lu-177)
Alpha (α)	High linear energy transfer (LET), very cytotoxic	Targeted alpha therapy (e.g., Ra-223, Ac-225)
Positron (β⁺)	Emits positrons detected by PET scanners	PET (e.g., F-18, Ga-68)

3. Mechanism of Action

Diagnostic Radiopharmaceuticals

• These agents localize in specific organs or tissues, depending on physiological or biochemical characteristics (e.g., glucose metabolism, receptor expression).

• The radioactive decay releases detectable gamma rays (SPECT) or positrons (PET), captured by imaging equipment to visualize anatomy and function.

Therapeutic Radiopharmaceuticals

• Deliver cytotoxic radiation selectively to target tissues such as tumors.

• Radiation destroys DNA in malignant cells, leading to cell death.

• Some agents are receptor-specific or antigen-targeted, enhancing specificity.

---

4. Formulation Components

Radiopharmaceuticals consist of:

1. Radionuclide (radioisotope): Provides radioactivity (e.g., Tc-99m, I-131)

2. Carrier molecule (ligand, peptide, antibody): Targets specific tissues or receptors (e.g., DOTATATE, PSMA, MIBG)

3. Chelator (optional): Binds radionuclide to the carrier molecule (e.g., DOTA, DTPA)

---

5. Examples of Common Radiopharmaceuticals

A. Diagnostic Agents

Name	Radionuclide	Use
FDG (Fluorodeoxyglucose)	F-18	PET imaging – cancer, brain, heart
Tc-99m MDP	Tc-99m	Bone scintigraphy
Tc-99m MAG3	Tc-99m	Renal imaging
I-123 MIBG	I-123	Neuroendocrine tumor imaging
Ga-68 DOTATATE	Ga-68	Somatostatin receptor imaging (NETs)
Rb-82	Rb-82	Myocardial perfusion PET

B. Therapeutic Agents

Name	Radionuclide	Indication
I-131 sodium iodide	I-131	Thyroid cancer, hyperthyroidism
Lu-177 DOTATATE	Lu-177	Neuroendocrine tumors
Lu-177 PSMA-617	Lu-177	Metastatic prostate cancer
Ra-223 dichloride	Ra-223	Bone metastases from prostate cancer
Y-90 ibritumomab tiuxetan (Zevalin)	Y-90	Non-Hodgkin lymphoma
Sm-153 EDTMP	Sm-153	Bone pain in metastasis
Ac-225 PSMA	Ac-225	Advanced prostate cancer (clinical trials)

6. Clinical Applications

A. Oncology

• Tumor detection and staging

• Tumor-specific receptor targeting

• Targeted radionuclide therapy (TRT)

B. Cardiology

• Myocardial perfusion imaging (MPI)

• Ischemia and viability assessment

C. Neurology

• Alzheimer’s disease (e.g., Amyloid PET tracers like F-18 florbetapir)

• Parkinson’s disease (e.g., DaTscan – I-123 ioflupane)

D. Endocrinology

• Thyroid function studies (I-123, I-131)

• Parathyroid localization (Tc-99m sestamibi)

E. Nephrology

• Renal perfusion and function assessment (MAG3, DTPA)

---

7. Theranostic Approach in Nuclear Medicine

Theranostics combines diagnosis and therapy using the same targeting vector but labeled with different isotopes:

Agent Pair	Diagnostic Isotope	Therapeutic Isotope
DOTATATE	Ga-68 (PET)	Lu-177 (therapy)
PSMA-617	Ga-68 (PET)	Lu-177, Ac-225
MIBG	I-123 (imaging)	I-131 (therapy)

This personalized approach helps in:

• Predicting therapeutic efficacy

• Monitoring treatment response

• Minimizing off-target toxicity

---

8. Administration and Dosimetry

• Routes: Mostly intravenous, occasionally oral (e.g., I-131), or inhalation

• Dosimetry: Radiation dose to tissues must be calculated based on:

  • Radioisotope properties

  • Patient-specific metabolism and excretion

  • Organ uptake (measured using pre-therapy scans)

---

9. Safety and Radiation Protection

Radiopharmaceuticals involve ionizing radiation; hence stringent safety protocols are necessary.

Key Considerations:

• Short half-life isotopes preferred to reduce prolonged radiation exposure

• Patient isolation (e.g., I-131 therapy)

• Use of lead shielding in preparation and transport

• Pregnancy and lactation contraindications due to fetal risk

• Radiation sickness is rare but possible at high doses

Monitoring:

• Whole-body and thyroid scans for uptake

• Blood counts for marrow toxicity (especially with beta/alpha emitters)

• Renal and hepatic function tests (for excretion monitoring)

---

10. Adverse Effects

Common Side Effects	Mechanism
Nausea, vomiting	Radiation-induced GI mucosal irritation
Sialadenitis	Salivary gland uptake (I-131)
Bone marrow suppression	Beta/alpha therapy agents
Hypothyroidism	Thyroid ablation (I-131)
Renal toxicity	With radiopeptide therapy (e.g., Lu-177)
Dry mouth, taste alteration	Radiation to oral glands

11. Regulatory Oversight and Quality Control

Radiopharmaceuticals are regulated under drug and radioactive material regulations, requiring dual oversight.

Agency	Role
FDA (U.S.)	Approval, labeling, pharmacovigilance
EMA (Europe)	Regulatory authorization and safety
Nuclear Regulatory Commission (NRC)	Radioactive material licensing
IAEA	Global standards, nuclear medicine safety
USP (United States Pharmacopeia)	Monographs for preparation and purity

Manufacturing Standards:

• GMP (Good Manufacturing Practices)

• Radiochemical purity > 90%

• Sterility and pyrogen testing

• Short preparation-to-use time (especially for short-lived isotopes)

---

12. Storage and Handling

• Radiopharmaceuticals must be stored in shielded containers in lead-lined storage

• Labeling includes:

  • Radionuclide name and activity (in MBq or mCi)

  • Date and time of calibration

• Transportation follows hazardous material regulations (e.g., UN 2915 label)

---

13. Future Trends and Innovations

• Alpha therapies (Ac-225, Bi-213, Th-227): Highly cytotoxic, ideal for micrometastases

• PET/MRI hybrid imaging: Enhanced resolution and tissue contrast

• Immune-targeted radiotracers: Anti-CD20, anti-PD-L1 linked to isotopes

• Radiolabeled nanomedicines: Enhanced delivery and stability

• Artificial intelligence in image analysis and personalized dosimetry

---

14. List of Common Radiopharmaceuticals by Radionuclide

Radionuclide	Half-life	Emission Type	Common Use
F-18	110 min	β⁺ (PET)	FDG PET for oncology, neurology, cardiology
Tc-99m	6 hours	γ (SPECT)	Bone, renal, cardiac, hepatobiliary imaging
I-123	13 hours	γ (SPECT)	Thyroid scans, MIBG
I-131	8 days	β⁻ and γ	Thyroid therapy, MIBG therapy
Ga-68	68 min	β⁺ (PET)	NETs (DOTATATE), prostate cancer (PSMA)
Lu-177	6.7 days	β⁻ and γ	NETs, prostate cancer
Ac-225	10 days	α	Advanced prostate cancer (experimental)
Ra-223	11.4 days	α	Bone metastases from prostate cancer